Definitive Statement Filed for Reverse Stock Split and New Dilutive Equity Plan

summarizeSummary

Curanex Pharmaceuticals filed a definitive statement confirming a reverse stock split to meet Nasdaq requirements and detailing a new equity plan that could significantly dilute existing shareholders.

check_boxKey Events · Corporate Governance and Compliance · CURX

• Definitive Information Statement Filed

  This DEF 14C finalizes the terms of actions previously disclosed in a preliminary filing, including a reverse stock split and a new equity incentive plan.

• Reverse Stock Split Approved

  Majority stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50, with the Board retaining discretion on the exact ratio and timing. This is primarily to regain compliance with Nasdaq's $1.00 minimum bid price requirement by November 2, 2026.

• New Equity Incentive Plan Adopted

  The 2026 Equity Incentive Plan authorizes the issuance of up to 5,700,000 shares of common stock, plus an annual increase of up to 4% of outstanding shares. This represents substantial potential dilution for current shareholders.

• Nasdaq Delisting Threat Remains

  The company received an extension until November 2, 2026, to meet Nasdaq's minimum bid price requirement. The reverse split is a direct response to this delisting threat.

auto_awesomeAnalysis · CURX · Life Sciences

Curanex Pharmaceuticals has filed a definitive information statement confirming the approval of a reverse stock split, intended to help the company regain compliance with Nasdaq's minimum bid price requirement. This action is critical for the micro-cap company to avoid delisting. Additionally, the filing details the adoption of a new equity incentive plan authorizing the issuance of up to 5.7 million shares, plus an annual evergreen provision of up to 4% of outstanding shares. This plan represents significant potential dilution for existing shareholders, especially for a company of this size.